Home > Oncology > ASCO GU 2022 > Prostate Cancer > PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Presented By
Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia
Conference
ASCO GU 2022
Trial
Phase 2, TheraP
In men with metastatic castration-resistant prostate cancer (mCRPC), high PSMA expression is predictive of a higher likelihood of favourable response to 177Lu-PSMA-617 (LuPSMA) than cabazitaxel. In addition, a high volume of disease on 18FDG PET is prognostic for worse outcome regardless of treatment. The TheraP trial (NCT03392428) showed that LuPSMA improved PSA ≥50% response rate (PSA50 RR), PSA progression-free survival (PFS), and radiographic PFS (rPFS) compared with cabazitaxel in mCRPC progressing after docetaxel [1]. In addition, it was hypothesised that a high PSMA expression would correlate to a better response to LuPSMA versus cabazitaxel, while a high FDG-positive tumour volume would correlate to a low response to either therapy. In other words, that PSMA PET would be a predictive biomarker and FDG PET a prognostic biomarker. Prof. ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on